Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03009214
Other study ID # AMC303-01
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date December 2016
Est. completion date May 7, 2021

Study information

Verified date May 2021
Source amcure GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a two part Phase I/Ib, open-label, non-randomized and multi-center, dose escalation study with a 3+3 design (Part 1) and an expansion cohort at the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) (Part 2). If MTD is not reached in Part 1, RP2D will be determined after completion of Part 1 considering safety and tolerability, also beyond the dose limiting toxicity (DLT) period, pharmacokinetic (PK) and pharmacodynamic (PD) results.


Recruitment information / eligibility

Status Completed
Enrollment 55
Est. completion date May 7, 2021
Est. primary completion date July 28, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Histologically confirmed and documented, advanced or metastatic, accessible malignant solid tumour of epithelial origin and for which no standard therapy exists or standard therapy has failed. 2. Presence of a measurable tumour according to RECIST 1.1. criteria 3. At least 4 weeks from the completion of any previous cytotoxic chemotherapy, 6 weeks from biological therapy (monoclonal antibodies) or cancer immunotherapy (immune checkpoint modulators) or 2 weeks from targeted therapy (receptor tyrosine kinase inhibitors) at time of administration of AMC303. 4. Male or female patients, at least 18 years of age 5. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1 6. Life expectancy > 12 weeks. 7. Adequate haematological function defined as - Absolute neutrophil count (ANC) > 1,500 / µL - Platelets > 100,000 / µL - Haemoglobin > 9 g /dL. 8. Adequate renal function defined as - Glomerular filtration rate (GFR) = 50 ml/min according to local laboratory standard or - Serum creatinine < 1.5 mg / dL. 9. Adequate hepatic function defined as - Total bilirubin < 1.5x institutional upper limit of normal (ULN) - AST, ALT = 3x institutional ULN or < 5x institutional ULN if known hepatic metastases - Alkaline phosphatase < 3x institutional ULN or < 5x institutional ULN if known hepatic metastases. 10. Patient may have central nervous system (CNS) involvement if metastases have been treated and are stable at least 4 weeks after completion of radiation therapy and/or surgery. Stable disease is defined as absence of new neurological symptoms, absence of the need for steroid therapy and radiographic confirmation of stable disease. Radiographic confirmation of stable disease 4 weeks after completion of radiation therapy is not required unless indicated by neurological examination. 11. All female subjects will be considered to be of childbearing potential unless they are postmenopausal (at least 12 months consecutive amenorrhea, in the appropriate age group and without other known or suspected cause), or have been sterilized surgically. For female participants and female partners of childbearing potential, willingness and able to use two forms of highly effective contraception methods (e.g. oral contraceptive and condom, intra-uterine device and condom) while on study and for 30 days after the last study treatment. For male participants or male partners of childbearing potential, willingness and able to use two forms of highly effective contraception methods (e.g. oral contraceptive and condom, intra-uterine device and condom,) while on study and for three months after the last study treatment. 12. Provision of signed Informed Consent prior to any study related procedure being performed Exclusion Criteria: 1. Receipt of any other investigational agent within 28 days prior to first administration of AMC303. Investigational monoclonal antibodies must not be given within 6 weeks before treatment start with AMC303. 2. Enrolment in another clinical study with an investigational drug 3. Presence of residual toxicities of CTCAE Grade > 1 after prior anti-tumour therapy within 2 weeks of first treatment with AMC303 with the exception of Grade 3 alopecia and infusion site reactions 4. Severe concurrent illness or psychiatric illness/social situation that would limit compliance with study requirements 5. Anticipation of major surgical procedures within first 4 weeks of first dose 6. Pregnancy or breast-feeding as determined by a serum pregnancy test (ß-HCG) at screening prior to administration of AMC303 and willingness to father a child or to become pregnant 7. Untreated acute infectious disease 8. Patient is known to be suffering from Acquired Immune Deficiency Syndrome (AIDS) or is known to be HIV seropositive without AIDS defining disease 9. Known chronic hepatitis B or C. 10. History of allergic reactions attributed to compounds of similar chemical or biological composition to AMC303. 11. Evidence of any other medical conditions that in the opinion of the investigator may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment-related complications 12. Previous malignant disease other than the target malignancy to be investigated within the last 5 years with the exception of basal or squamous carcinoma of the skin or cervical carcinoma in situ 13. Legal incapacity or limited legal capacity

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AMC303
AMC303 is a CD44v6 inhibitor blocking receptor tyrosine kinase (RTK) pathways

Locations

Country Name City State
Belgium Cliniques Universitaires Saint Luc Brussel
Belgium Jules Bordet Instiut Brussels
Spain Vall d'Hebron Institute of Oncology (VHIO) Barcelona
Spain Institut Català d'Oncologia, Hospital Duran i Reynals L'Hospitalet de Llobregat Barcelona
Spain START Madrid-CIOCC, Centro Integral Oncológico Clara Campal Madiedo
Spain Hospital Universitario Virgen de la Victoria Málaga
Spain Instituto de Investigación Sanitaria INCLIVA, Hospital Clínico de Valencia Valencia

Sponsors (1)

Lead Sponsor Collaborator
amcure GmbH

Countries where clinical trial is conducted

Belgium,  Spain, 

References & Publications (1)

Matzke-Ogi A, Jannasch K, Shatirishvili M, Fuchs B, Chiblak S, Morton J, Tawk B, Lindner T, Sansom O, Alves F, Warth A, Schwager C, Mier W, Kleeff J, Ponta H, Abdollahi A, Orian-Rousseau V. Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling. Gastroenterology. 2016 Feb;150(2):513-25.e10. doi: 10.1053/j.gastro.2015.10.020. Epub 2015 Oct 24. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and tolerability of AMC303 Number of patients with treatment-related adverse events as assessed by CTCAE v4.0 6 months
Secondary Pharmacokinetic properties of AMC303 (Cmax) Determine maximum plasma concentration (Cmax) 2 days
Secondary Pharmacokinetic properties of AMC303 (AUC) Determine systemic exposure (AUC) after intravenous infusion 2 days
Secondary Pharmacokinetic properties of AMC303 (t1/2) Determine half-life of AMC303 after intravenous infusion 2 days
Secondary Response rate of treatment with AMC303 in patients with metastatic solid tumors Determination of the complete response (CR) and partial response (PR) in patients treated with AMC303 12 months
See also
  Status Clinical Trial Phase
Terminated NCT01846429 - Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain Phase 1
Completed NCT01359982 - Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects Phase 1
Completed NCT00725634 - A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma Phase 1
Completed NCT01648764 - A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread Phase 1
Recruiting NCT04083599 - GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT05141474 - Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors Early Phase 1
Active, not recruiting NCT02999750 - EXtendedAnalysis for Cancer Treatment N/A
Completed NCT01457118 - An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies Phase 2
Active, not recruiting NCT05539157 - Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors Phase 1
Recruiting NCT04571892 - A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT05468359 - Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients Phase 1/Phase 2
Recruiting NCT04168528 - Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT Phase 1/Phase 2
Recruiting NCT04145622 - Study of Ifinatamab Deruxtecan (I-DXd) in Participants With Advanced Solid Malignant Tumors Phase 1/Phase 2
Recruiting NCT06057038 - A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors Phase 1
Completed NCT02844400 - Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation
Completed NCT00452413 - A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer Phase 1/Phase 2
Completed NCT03553108 - A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours. Phase 1
Recruiting NCT04076137 - Targeted T-cell Therapy in Solid Tumors Early Phase 1
Terminated NCT03192345 - A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors Phase 1
Completed NCT02754141 - An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab Phase 1/Phase 2

External Links